|

Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU

RECRUITINGSponsored by Miltenyi Biomedicine GmbH
Actively Recruiting
SponsorMiltenyi Biomedicine GmbH
Started2024-05-15
Est. completion2039-12-01
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations5 sites
View on ClinicalTrials.gov →

NCT06116110

Summary

This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Received zamtocabtagene autoleucel in a Miltenyi Biomedicine-sponsored clinical study and have either completed the study or have discontinued early from the study.
* Provided written informed consent to participate in this study.

Exclusion Criteria:

* None

Conditions2

CancerNon-hodgkin Lymphoma

Locations5 sites

California

1 site
Stanford University
Stanford, California, 94305
Christina Tranctran13@stanford.edu

Connecticut

1 site
Yale University
New Haven, Connecticut, 06520
Jialing Zhangjialing.zhang@yale.edu

Maryland

1 site
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
Baltimore, Maryland, 21201
Nancy Hardy, MDnhardy1@umm.edu

Massachusetts

1 site
Dana Farber Cancer Institute
Boston, Massachusetts, 02215
Christopher SimmonsChristopher_Simmons@DFCI.HARVARD.EDU

Wisconsin

1 site
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226
Hailey McArtheyhmcarthey@mcw.edu

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.